AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.
The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.
Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.